IRulya Therapeutics Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
IRLA
- Investments
-
3
- Share Price
-
$39.88
- (As of Friday Closing)
IRulya Therapeutics General Information
Description
IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.
Contact Information
Website
www.irulya.comCorporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
Corporate Office
- 101 College Street
- Suite 210
- New Haven, CT 06510
- United States
IRulya Therapeutics Timeline
IRulya Therapeutics Stock Performance
As of 20-Nov-2026, IRulya Therapeutics’s stock price is $39.88. Its current market cap is $432M with 10.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $39.88 | $40.07 | $15.10 - $909.98 | $432M | 10.8M | 62.2K | -$162.19 |
IRulya Therapeutics Financials Summary
As of 30-Sep-2026, IRulya Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 59,369 | 178,238 | 49,886 | (38,152) |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (111,063) | (81,867) | (59,484) | (34,738) |
| Net Income | (106,778) | (83,979) | (56,828) | (31,385) |
| Total Assets | 106,472 | 93,523 | 114,478 | 167,900 |
| Total Debt | 0 | 18,471 | 14,811 | 13,814 |
IRulya Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
IRulya Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
IRulya Therapeutics Comparisons
Industry
Financing
Details
IRulya Therapeutics Competitors (135)
One of IRulya Therapeutics’s 135 competitors is Design Therapeutics, a Formerly VC-backed company based in Carlsbad, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Design Therapeutics | Formerly VC-backed | Carlsbad, CA | ||||
| Harmony Biosciences Holdings | Formerly VC-backed | Plymouth Meeting, PA | ||||
| Rein Therapeutics | Formerly VC-backed | Austin, TX | ||||
| Tenax Therapeutics | Formerly VC-backed | Chapel Hill, NC | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA |
IRulya Therapeutics Patents
IRulya Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025158249-A1 | Intra-erythrocyte dexamethasone for treatment of ataxia-telangiectasia | Pending | 25-Jan-2024 | ||
| AU-2023217975-A1 | Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene | Inactive | 14-Feb-2022 | ||
| EP-4479527-A1 | Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene | Inactive | 14-Feb-2022 | ||
| US-20250297235-A1 | Variants of the human atm protein for the treatment of diseases related to at least one mutation of the atm gene | Pending | 14-Feb-2022 | ||
| AU-2022279663-A1 | Engineering new metabolic pathways in isolated cells for the degradation of guanidinoacetic acid and simultaneous production of creatine | Inactive | 27-May-2021 | C12N9/1007 |
IRulya Therapeutics Signals
IRulya Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
IRulya Therapeutics Acquisitions (3)
IRulya Therapeutics’s most recent deal was a Merger/Acquisition with OrphAI Therapeutics for . The deal was made on 18-May-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OrphAI Therapeutics | 18-May-2026 | Merger/Acquisition | Drug Discovery | ||
| EryDel | 20-Oct-2023 | Merger/Acquisition | Drug Delivery | ||
| Novosteo | 19-May-2022 | Merger/Acquisition | Pharmaceuticals |
IRulya Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.2 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
IRulya Therapeutics Exits (1)
IRulya Therapeutics’s most recent exit was on 20-Oct-2023 from EryDel. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| EryDel | 20-Oct-2023 | Completed |
|
IRulya Therapeutics FAQs
-
When was IRulya Therapeutics founded?
IRulya Therapeutics was founded in 2012.
-
Where is IRulya Therapeutics headquartered?
IRulya Therapeutics is headquartered in New Haven, CT.
-
What is the size of IRulya Therapeutics?
IRulya Therapeutics has 38 total employees.
-
What industry is IRulya Therapeutics in?
IRulya Therapeutics’s primary industry is Drug Discovery.
-
Is IRulya Therapeutics a private or public company?
IRulya Therapeutics is a Public company.
-
What is IRulya Therapeutics’s stock symbol?
The ticker symbol for IRulya Therapeutics is IRLA.
-
What is the current stock price of IRulya Therapeutics?
As of 20-Nov-2026 the stock price of IRulya Therapeutics is $39.88.
-
What is the current market cap of IRulya Therapeutics?
The current market capitalization of IRulya Therapeutics is $432M.
-
Who are IRulya Therapeutics’s competitors?
Design Therapeutics, Harmony Biosciences Holdings, Rein Therapeutics, Tenax Therapeutics, and Inovio Pharmaceuticals are some of the 135 competitors of IRulya Therapeutics.
-
What is IRulya Therapeutics’s annual earnings per share (EPS)?
IRulya Therapeutics’s EPS for 12 months was -$162.19.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process